27th Jun 2014 14:53
27 June 2014
("Biofrontera" or "the Company")
Result of AGM
Biofrontera AG (AIM/FSE:B8F), the European biopharmaceutical company, announces that at the Company's Annual General Meeting ('AGM') held earlier today, all of the resolutions proposed, as set out in the Notice of the AGM, were duly passed.
The Annual Report and Accounts for the year ended 31 December is available on the website -
www.biofrontera/com.
Enquiries
Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer , Chief Financial Officer
| + 49 (0) 214 87 63 2 22 www.biofrontera.com
|
finnCap (Nomad and Broker) Geoff Nash / Christopher Raggett (Corporate Finance) Steven Norcross(Corporate Broking)
| +44(0) 20 7220 0500 |
Seton Services Limited (IR) Toni Vallen
| +44 (0) 20 7603 6797 |
Gable Communications Justine James / John Bick | +44 (0) 20 7193 7463 +44 (0) 7872 061007 |
Notes to Editors:
Biofrontera AG (AIM / FSE: B8F) is a biopharmaceutical company specialising in the development and distribution of dermatological drugs and medical cosmetics for the treatment and care of skin diseases. Biofrontera's main product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate Actinic Keratosis (superficial skin cancer) by photodynamic therapy (light therapy). Biofrontera is the first small German pharmaceutical company to receive a centralized approval for a drug developed in-house. The Company is looking to further develop Ameluz for use in Basal Cell Carcinoma and is currently progressing through regulatory approvals to sell the product in other territories, in particular the largest pharmaceutical market, the USA.
In addition, the Company markets the Belixos cosmetic series with plant extracts, currently available in cream and liquid formulations which offer nurturing and regenerating effects for people suffering from pruritus, dry skin or chronic ailments such as eczema or psoriasis.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the CEO, and is headquartered in Leverkusen, Germany.
www.biofrontera.com
Related Shares:
B8F.L